

Special Issue

Cardiovascular Disease Prevention in the Era of Personalized Medicine

Message from the Guest Editor

Dear colleagues, Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Prevention of CVD is based on the management of cardiovascular risk factors, including hypertension, dyslipidemia, diabetes mellitus, obesity, and smoking. Antiplatelet and anticoagulant treatment is also needed in certain subgroups. With the introduction of several novel pharmacological agents, personalized decisions can be made to optimize the safety and efficacy of the treatment of these risk factors. In this Special Issue, the management of the major modifiable cardiovascular risk factors is discussed. Given the multitude of therapeutic options, an evidence-based strategy is essential to reducing cardiovascular morbidity and mortality, particularly in high-risk patients with multiple comorbidities.

Guest Editor

Dr. Konstantinos Tziomalos

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, Greece

Deadline for manuscript submissions

closed (22 February 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/57363

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).